Opinion|Videos|May 30, 2025
Personalized Care: How Do NSCLC Treatment Modifications and Patient-Specific Factors Impact Health Outcomes?
Author(s)Lauren Ledbetter, PharmD, BCOP
A panelist discusses how maintaining efficacy while preserving quality of life requires personalized approaches including dose adjustments or agent rotation based on specific toxicities, and how selecting the appropriate EGFR inhibitor depends on patient comorbidities, performance status, baseline conditions (such as interstitial lung disease or cardiac issues), and patient preferences.
Advertisement
Episodes in this series
Balancing Efficacy and Quality of Life
- Approaches to managing toxicity:
- Dose adjustments within recommended ranges
- Temporary holds until toxicity resolves
- Rotation to alternative agents within the same class
- EGFR tyrosine kinase inhibitor selection factors:
- Consider patient comorbidities and concomitant medications
- Baseline interstitial lung disease: may favor erlotinib over osimertinib
- Cardiac comorbidities (low ejection fraction, QTc prolongation): may favor erlotinib
- Poor performance status: minimize agents that could contribute to toxicities
- Patient preferences and lifestyle considerations significantly impact adherence
Advertisement
Related to this article
An MRD-guided strategy incorporating teclistamab-daratumumab intensification produced deep responses in newly diagnosed high-risk multiple myeloma, although infections affected more than three-quarters of treated patients.
Researchers found substantial overlap in autonomic symptoms, orthostatic tachycardia, and functional impairment between long COVID and POTS.
Phase 2 MILESTONE results suggest that postinduction minimal residual disease (MRD) negativity can identify a small subset of transplant-eligible patients with newly diagnosed multiple myeloma who may defer autologous stem cell transplantation.
A phase 3 trial shows etentamig boosts response and delays progression in triple-class exposed RRMM.
Fixed-duration KRd slowed progression in high-risk smoldering myeloma, but high rates of severe toxicity temper enthusiasm.
A review of 69 studies finds influenza vaccines continue to reduce hospitalization and death, with no new safety concerns.
IRAKLIA shows isatuximab OBI boosts comfort and satisfaction vs IV in multiple myeloma, enabling fast at-home dosing with strong completion.
Gut microbiome disruption from anti-anaerobic antibiotics weakens CAR T cell therapy, raising relapse and CRS/ICANS risk; stewardship and microbiome repair may improve cancer outcomes.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
2
After 180 Years, Multiple Myeloma Gets a Definition of Cure
3
Teclistamab-Daratumumab Intensification Achieves 73% MRD-Negative CR Rate in High-Risk Multiple Myeloma
4
Influenza Vaccines Continue to Reduce Severe Disease and Death Across High-Risk Groups, Evidence Review Finds
5